Literature DB >> 28139616

[Recommendations on the algorithms for drug choice and risk management plan in the treatment of patients with remitting multiple sclerosis with natalizumab].

M V Davydovskaya1, N V Khachanova1, E P Evdoshenko2, I N Pronin3, A N Boiko4, M N Zakharova5, V M Alifirova6, E A Turova7, N A Malkova8, S A Sivertseva9, L A Tsukurova10, A A Skoromets11, I Yu Solodun12.   

Abstract

Entities:  

Year:  2016        PMID： 28139616     DOI： 10.17116/jnevro201611610279-97

Source DB:  PubMed          Journal:  Zh Nevrol Psikhiatr Im S S Korsakova        ISSN： 1997-7298


× No keyword cloud information.
  1 in total

1.  Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia.

Authors:  Evgeniy Evdoshenko; Alexandra Stepanova; Maria Shumilina; Maria Davydovskaya; Natalia Khachanova; Nikolay Neofidov; Ivan Kalinin; Ekaterina Popova; Ekaterina Dubchenko; Natalia Pozhidaeva; Andrey Volkov; Stella Sivertseva; Anna Prilenskaya; Nadezhda Malkova; Denis Korobko; Ilona Vergunova; Sergey Shchur; Gleb Makshakov
Journal:  PLoS One       Date:  2019-05-28       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.